Nā huahana

Ua hōʻike ʻia ka protein cerebral dopamine neurotrophic factor (CDNF) e pale i ke ala dopaminergic nigrostriatal ke hāʻawi ʻia ma ke ʻano he intrastriatal infusions i nā ʻiole a me nā ʻiole o ka maʻi o Parkinson (PD).Ma kēia haʻawina, ua loiloi mākou i ka hopena neuroprotective o CDNF i hāʻawi ʻia me kahi recombinant adeno-associated viral (AAV) serotype 2 vector i loko o kahi ʻiole 6-hydroxydopamine (6-OHDA) model o PD.AAV2 vectors encoding CDNF, glial cell line-derived neurotrophic factor (GDNF), or green fluorescent protein ua hoʻokomo ʻia i loko o ka ʻiole striatum.Ua hōʻike ʻia ka hōʻike ʻana o ka protein i kā mākou vector AAV2 i hāʻawi maikaʻi i nā genes neurotrophic factor i loko o ka lolo a hāʻawi i kahi hōʻike lōʻihi o nā protein.ʻElua pule ma hope o ka hoʻokomo ʻana i ka vector AAV2, ua hoʻokomo ʻia ʻo 6-OHDA i loko o ka striatum ʻiole, e hana ana i kahi degeneration holomua o ka ʻōnaehana dopaminergic nigrostriatal.ʻO ka hoʻomaʻamaʻa ʻana me AAV2-CDNF ka hopena i ka emi ʻana o ka amphetamine-induced ipsilateral rotations ʻoiai hāʻawi ia i ka pale hapa wale o tyrosine hydroxylase (TH) -immunoreactive cell i loko o ka ʻiole substantia nigra pars compacta a me ka TH-reactive fibers i loko o ka striatum.Hāʻawi nā hopena mai kēia noiʻi ʻana i nā hōʻike hou e hiki ke noʻonoʻo ʻia ʻo CDNF he lapaʻau kūpono no ka maʻi o Parkinson